The Number of Metastatic Lymph Nodes is a Useful Predictive Factor for Recurrence after Surgery for Nonmetastatic Nonfunctional Neuroendocrine Neoplasm of the Pancreas.
Journal
Gastroenterology research and practice
ISSN: 1687-6121
Titre abrégé: Gastroenterol Res Pract
Pays: Egypt
ID NLM: 101475557
Informations de publication
Date de publication:
2019
2019
Historique:
received:
31
12
2018
revised:
28
02
2019
accepted:
19
03
2019
entrez:
12
6
2019
pubmed:
12
6
2019
medline:
12
6
2019
Statut:
epublish
Résumé
Nodal involvement (actually categorized as positive or negative) is an important prognostic factor after surgery for pancreatic neuroendocrine neoplasms (pNENs). We aim to evaluate the predictive role of the number of nodal metastases after pancreatic resection for pNENs. We analyzed from a prospectively maintained database all pancreatic resections for nonmetastatic nonfunctioning pNENs performed in our institution from 2011 to 2016. According to the number of nodal metastases, enhancing the actual categorization, we distinguished the following: N0, no nodal metastases; N1, 1-3 metastatic lymph nodes; and N2, metastases in 4 or more regional lymph nodes. Recurrence and disease-free survival (DFS) were evaluated. The predictive value in terms of recurrence for each clinicopathological data, including the number of metastatic lymph nodes, was calculated. Univariate and multivariate analyses were conducted. 77 patients underwent pancreatic surgery for pNENs. N0, N1, and N2 resections were found in 52 (67.5%), 16 (20.8%), and 9 (11.7%) cases, respectively. Mean follow-up of the entire cohort was 48 (±25) months. The recurrence rate was 11.8%, and the mean time of recurrence was 12 (±14) months. DFS was 83.7 months (76.0 - 91.5). At a univariate analysis, factors associated with recurrence were mitotic count (OR 1.19,
Identifiants
pubmed: 31182959
doi: 10.1155/2019/6856329
pmc: PMC6512048
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6856329Références
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Virchows Arch. 2006 Oct;449(4):395-401
pubmed: 16967267
Br J Surg. 2008 Mar;95(3):357-62
pubmed: 17933001
Curr Opin Oncol. 2012 Jan;24(1):46-55
pubmed: 22080942
Ann Surg. 2014 Feb;259(2):197-203
pubmed: 24253141
Ann Surg. 2015 May;261(5):961-9
pubmed: 24979603
Surgery. 2014 Sep;156(3):591-600
pubmed: 25061003
J Gastrointest Surg. 2015 Jan;19(1):152-60; discussion 160
pubmed: 25118642
Neuroendocrinology. 2016;103(2):153-71
pubmed: 26742109
Surgery. 2017 Mar;161(3):584-591
pubmed: 28040257
Ann Surg. 2018 Jun;267(6):1148-1154
pubmed: 28594340
Int J Surg. 2017 Dec;48:142-148
pubmed: 29107188
Eur J Surg Oncol. 2018 Jun;44(6):778-783
pubmed: 29610023
Surgery. 2019 Apr;165(4):672-685
pubmed: 30558808